Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

HLA-DRB3 Antikörper (AA 111-227) (Biotin)

HLA-DRB3 Reaktivität: Human ELISA Wirt: Kaninchen Polyclonal Biotin
Produktnummer ABIN7155606
  • Target Alle HLA-DRB3 Antikörper anzeigen
    HLA-DRB3 (Major Histocompatibility Complex, Class II, DR beta 3 (HLA-DRB3))
    Bindungsspezifität
    • 5
    • 4
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 111-227
    Reaktivität
    • 28
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 24
    • 4
    Kaninchen
    Klonalität
    • 26
    • 2
    Polyklonal
    Konjugat
    • 19
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser HLA-DRB3 Antikörper ist konjugiert mit Biotin
    Applikation
    • 12
    • 6
    • 5
    • 4
    • 3
    • 2
    • 2
    ELISA
    Kreuzreaktivität
    Human
    Aufreinigung
    >95%, Protein G purified
    Immunogen
    Recombinant Human HLA class II histocompatibility antigen, DR beta 3 chain protein (111-227AA)
    Isotyp
    IgG
    Top Product
    Discover our top product HLA-DRB3 Primärantikörper
  • Applikationshinweise
    Optimal working dilution should be determined by the investigator.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C,-80 °C
    Informationen zur Lagerung
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Target
    HLA-DRB3 (Major Histocompatibility Complex, Class II, DR beta 3 (HLA-DRB3))
    Andere Bezeichnung
    HLA-DRB3 (HLA-DRB3 Produkte)
    Synonyme
    HLA-DR3B antikoerper, BLA-DRB3 antikoerper, Bota-DRB01 antikoerper, Bota-DRB02 antikoerper, Bota-DRB04 antikoerper, Bota-DRB07 antikoerper, Bota-DRB21 antikoerper, Bota-DRB22 antikoerper, LA-DRB antikoerper, major histocompatibility complex, class II, DR beta 3 antikoerper, major histocompatibility complex, class II, DRB3 antikoerper, HLA-DRB3 antikoerper, BOLA-DRB3 antikoerper
    Hintergrund

    Background: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

    Aliases: DR beta 3 chain antibody, DR7 antibody, DRB3_HUMAN antibody, HLA class II histocompatibility antigen antibody, HLA class II histocompatibility antigen DR beta 3 chain antibody, HLA class II histocompatibility antigen DRB1 7 beta chain antibody, HLA DR3B antibody, HLA-DRB3 antibody, Human leucocyte antigen DRB3 antibody, Major histocompatibility complex class II DR beta 3 antibody, MGC117330 antibody, MHC class II antigen DR beta 3 chain antibody, MHC class II antigen DRB3 antibody, MHC class II HLA DR beta 3 chain antibody

    UniProt
    P79483
    Pathways
    T-Zell Rezeptor Signalweg, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
Sie sind hier: